Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ...
Immunic, Inc. announces enrollment of the first patient in a phase 2 clinical trial of vidofludimus calcium for Post COVID Syndrome, aiming to reduce fatigue and Epstein-Barr virus reactivation, with potential implications for multiple sclerosis treatment.
Reference News
Immunic, Inc. announces enrollment of the first patient in a phase 2 clinical trial of vidofludimus calcium for Post COVID Syndrome, aiming to reduce fatigue and Epstein-Barr virus reactivation, with potential implications for multiple sclerosis treatment.
Immunic, Inc. enrolls first patient in phase 2 trial of vidofludimus calcium for Post COVID Syndrome, aiming to reduce fatigue and Epstein-Barr virus reactivation, with potential implications for multiple sclerosis treatment.
First patient enrolled in a phase 2 trial of vidofludimus calcium for Post COVID Syndrome, aiming to reduce inflammation and fatigue, with potential to prevent Epstein-Barr virus reactivation.